Long QT syndrome is the most common cardiac arrhythmic disorder, predisposing to sudden cardiac death. There is tremendous genetic heterogeneity leading to long QT syndrome, which leads to considerable variations in disease severity and clinical course. Drug treatments are often ineffective, producing adverse effects in certain populations and prediction of the risk of sudden cardiac death remains fairly primitive. The recent advent of new technological breakthroughs, such as induced pluripotent stem cells (iPSCs), provides an unprecedented opportunity to study associations between genetic variability, drug responsiveness, and disease susceptibility. In addition, the biology of long QT-induced arrhythmia is largely quantifiable and thus amendable to a systems biology approach. The overarching goal of our Systems Biology Collaborative R01 Proposal is to develop an integrative experimental and computational approach to predict patient specific drug responses. To this end, we propose to utilize experimental data from patient-specific iPSC-derived cardiomyocytes (iPSC-CMs) in conjunction with clinical and genomic data, to construct the first, to our knowledge, patient-specific computational model of cardiac electrical activity. We hypothesize that we can use this model to improve our capability to predict arrhythmia susceptibility based on patient genotype as well as drug-response phenotypes associated with genetic variations in silico. We have assembled a team of highly accomplished researchers in cardiac stem cell biology, genomics, pharmacogenomics, molecular genetics/epigenetics, bioinformatics, and in silico modeling. We are well positioned to achieve the project goals within five years. The ability to predict QT response of an individual patient based on their genetic profile would be a novel personalized approach to better understand the mechanisms underlying sudden cardiac death that could ultimately revolutionize treatment strategies.

Public Health Relevance

The emergence of systems biology, which synergistically combines experimental and bioinformatics approaches, offers an analytical framework to capture the molecular complexity of human cardiac disease while offering computational models to predict individual disease manifestations and design targeted therapies. In this proposal, we outline a detailed multidisciplinary research strategy that combines experimental results from patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), clinical, genomic, pharmacogenomics, and in silico modeling data in order to construct a novel patient-specific computational model of cardiac electrophysiology. This new integrated in vitro and in silico paradigm will enable the assessment of patient proarrhythmic risk and could be used to decipher mechanisms of disease and to devise tailored therapeutic therapies for sudden cardiac death.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL128170-01
Application #
8927808
Study Section
Special Emphasis Panel (ZRG1-VH-D (55))
Program Officer
Krull, Holly
Project Start
2015-09-15
Project End
2019-05-31
Budget Start
2015-09-15
Budget End
2016-05-31
Support Year
1
Fiscal Year
2015
Total Cost
$797,787
Indirect Cost
$262,803
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304
Garg, Priyanka; Garg, Vivek; Shrestha, Rajani et al. (2018) Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as Models for Cardiac Channelopathies: A Primer for Non-Electrophysiologists. Circ Res 123:224-243
Churko, Jared M; Garg, Priyanka; Treutlein, Barbara et al. (2018) Defining human cardiac transcription factor hierarchies using integrated single-cell heterogeneity analysis. Nat Commun 9:4906
Wacker, Soren; Noskov, Sergei Yu (2018) Performance of Machine Learning Algorithms for Qualitative and Quantitative Prediction Drug Blockade of hERG1 channel. Comput Toxicol 6:55-63
Cao, Y; Chen, H; Qiu, R et al. (2018) Universal intracellular biomolecule delivery with precise dosage control. Sci Adv 4:eaat8131
Vorobyov, Igor; Clancy, Colleen E (2018) Sex, drugs, and funky rhythms. Heart Rhythm 15:485-486
Lee, Jaecheol; Shao, Ning-Yi; Paik, David T et al. (2018) SETD7 Drives Cardiac Lineage Commitment through Stage-Specific Transcriptional Activation. Cell Stem Cell 22:428-444.e5
Wnorowski, Alexa; Yang, Huaxiao; Wu, Joseph C (2018) Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models. Adv Drug Deliv Rev :
Liu, Qing; Van Bortle, Kevin; Zhang, Yue et al. (2018) Disruption of mesoderm formation during cardiac differentiation due to developmental exposure to 13-cis-retinoic acid. Sci Rep 8:12960
Argenziano, Mariana; Lambers, Erin; Hong, Liang et al. (2018) Electrophysiologic Characterization of Calcium Handling in Human Induced Pluripotent Stem Cell-Derived Atrial Cardiomyocytes. Stem Cell Reports 10:1867-1878
Zhang, Joe Z; Guo, Hongchao; Wu, Joseph C (2018) Applications of genetically engineered human pluripotent stem cell reporters in cardiac stem cell biology. Curr Opin Biotechnol 52:66-73

Showing the most recent 10 out of 41 publications